华森制药(002907) - 2024 Q3 - 季度财报

Financial Performance - The company achieved operating revenue of CNY 196,371,096.40 in Q3 2024, representing a year-on-year increase of 26.85%[3] - Net profit attributable to shareholders reached CNY 27,361,939.51, a significant increase of 701.72% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was CNY 18,470,701.55, up 1,075.67% year-on-year[3] - The basic and diluted earnings per share were CNY 0.0655, reflecting a 698.78% increase from the previous year[3] - Net profit for Q3 2024 reached CNY 74,576,835.63, representing a significant increase of 66.7% from CNY 44,775,006.77 in Q3 2023[17] - The total comprehensive income attributable to the parent company for Q3 2024 was CNY 74,402,990.17, compared to CNY 45,426,718.47 in Q3 2023, representing an increase of approximately 63.9%[18] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.1786, up from CNY 0.1072 in Q3 2023, indicating a growth of 66.5%[18] Revenue and Sales - The revenue from the five key traditional Chinese medicine products grew by 24.49% year-on-year during the reporting period[7] - The sales revenue of PEG 4000 and aluminum magnesium chewable tablets increased by 47.88% in Q3 2024[7] - The total operating revenue for Q3 2024 was CNY 614,223,361.57, an increase of 19.2% compared to CNY 515,257,554.58 in Q3 2023[16] Assets and Equity - The company's total assets at the end of the reporting period were CNY 1,911,716,297.46, an increase of 3.25% from the end of the previous year[3] - The company's total equity attributable to shareholders increased to CNY 1,657,277,314.49, a rise of 2.43% from the previous year[3] - The total assets of the company as of Q3 2024 were CNY 1,911,716,297.46, an increase from CNY 1,851,453,889.14 in the previous year[16] - The equity attributable to shareholders of the parent company increased to CNY 1,657,277,314.49 from CNY 1,617,921,007.43, a growth of 2.4%[16] Cash Flow - The net cash flow from operating activities decreased by 40.71% year-on-year, primarily due to the absence of large cash inflows from restricted funds released in the previous year[8] - Cash flow from operating activities for the current period was CNY 106,880,577.05, down 40.6% from CNY 180,280,978.10 in the previous year[20] - The ending balance of cash and cash equivalents was CNY 271,459,375.70, down from CNY 453,534,336.74 at the end of Q3 2023, reflecting a decrease of 40.1%[21] - The company's cash and cash equivalents decreased from 437,564,819.14 CNY at the beginning of the period to 271,460,383.50 CNY at the end of the period[14] - The net increase in cash and cash equivalents dropped by 447.44% to -166,105,443.44 CNY, influenced by the absence of large cash inflows from the previous year and increased financial product purchases[11] Expenses and Liabilities - The total operating costs for Q3 2024 were CNY 534,304,062.41, up from CNY 467,711,274.31 in the same period last year, reflecting a year-over-year increase of 14.2%[16] - Financial expenses decreased by 50.45% to -9,592,891.17 CNY, primarily due to increased interest income and no loan interest incurred[10] - Credit impairment losses surged by 334.62% to -3,861,266.09 CNY, primarily due to increased bad debt provisions from rising accounts receivable[10] - The total liabilities increased to CNY 254,438,982.97 from CNY 233,532,881.71, reflecting an increase of 8.5% year-over-year[16] Research and Development - Research and development expenses for Q3 2024 were CNY 38,987,662.38, down 21.0% from CNY 49,402,354.90 in Q3 2023[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,294, with the largest shareholder holding 45.04% of the shares[12] Other Income and Government Subsidies - The company received government subsidies related to the HSN002 project, contributing to the increase in other income[8] - Other income increased by 97.25% to 17,066,173.96 CNY, mainly from increased government subsidies received[10] Investment Activities - Total cash inflow from investment activities was CNY 214,694,231.30, significantly higher than CNY 540,363.25 in the same period last year[20] - Net cash flow from investing activities worsened by 131.65% to -237,306,294.89 CNY, mainly due to increased purchases of financial products[11]